Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1626 1627 1674
This examiner grants 51% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18028311 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | Final Rejection | The Regents of the University of California |
| 18015387 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Final Rejection | Merck Sharp & Dohme LLC |
| 17917538 | COMPOSITIONS AND METHODS TO INHIBIT FOULING OF AMMONIUM SALTS | Final Rejection | ECOLAB USA INC. |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | Final Rejection | Novartis AG |
| 18532710 | NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE, SALT FORMS THEREOF, AND PROCESSES TO OBTAIN | Non-Final OA | Merck Patent GmbH |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | Non-Final OA | The General Hospital Corporation |
| 18468907 | C19 SCAFFOLDS AND STEROIDS AND METHODS OF USE AND MANUFACTURE THEREOF | Non-Final OA | Trustees of Dartmouth College |
| 18285650 | METHODS FOR OPTIMIZING THE TREATMENT OF COLORECTAL CANCER | Non-Final OA | Brown University |
| 18557236 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 18020025 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Non-Final OA | CORNELL UNIVERSITY |
| 18020019 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Non-Final OA | CORNELL UNIVERSITY |
| 17769307 | METHODS OF INHIBITING LIVER-TYPE GLUTAMINASE, GLS2 | Non-Final OA | CORNELL UNIVERSITY |
| 17921369 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | Final Rejection | Lonza Greenwood LLC |
| 18020089 | USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME AND PEGASPARGASE | Non-Final OA | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy